We are so glad you’re here! We want this page to be your home on the web where you can come to learn about the latest news affecting lung cancer patients, get support from stories shared by other patients, and maybe tell your own.
We also want you to know that we are here for you! If you have questions about information we have here, navigating the complex path of cancer treatment, or anything else, please don’t hesitate to get in touch with us. Your message will be delivered directly to Danielle Hicks (Director of Patient Services and Programs), Michele Zeh (Patient Navigation and Services Coordinator), and Guneet Walia, PhD (Director of Research and Medical Affairs). They are always happy to hear from you.
Also, if you are ROS1-positive, we have a special portal area dedicated to ROS1ers. Please click this link to go there.
Regardless of where you are on your cancer journey, ALCF is with you.
Latest News for Patients
Congratulations, Merck, for the approval of KEYTRUDA® in first-line combo therapy irrespective of PD-1 expression. The improved responses seen with KEYTRUDA® plus pemetrexed/carboplatin regimen are significant, and highlight the importance of finding new approaches that address the unmet needs of patients with metastatic nonsquamous non-small cell lung cancer. Read the full press release here
A new study led by researchers at the Indiana University Melvin and Bren Simon Cancer Center may help answer questions about the role of immunotherapy in combination with chemotherapy in treating lung cancer patients whose disease worsened after initial response to immunotherapy. The randomized phase II study, known as HCRN LUN15-233, involves Taxotere® with or… Read More
The Addario Lung Cancer Medical Institute’s (ALCMI) CASTLE study provides a unique foundational resource enabling scientists to ask and answer critical questions around the biology of lung cancer, and has directly facilitated a number of innovative research efforts. The CASTLE specimens and data are being used to the benefit of patients while advancing lung cancer… Read More